Science Corporation's Max Hodak Implants Vision Chip in First Stargardt Disease Patient

Max Hodak, CEO of Science Corporation, announced the successful implantation of the PRIMA vision restoration chip in the first patient with Stargardt disease. This hereditary condition progressively damages central vision, affecting approximately 150,000 people globally. The PRIMA project is part of a broader initiative to develop advanced brain-computer interfaces, with the potential to treat various visual impairments.

The significance of this development lies in its innovative approach to restoring vision by utilizing a microchip that acts as an artificial photoreceptor. The patient, who underwent surgery at Sydney Eye Hospital in May, has already shown promising results in rehabilitation training, being able to recognize letters and words. This technology could pave the way for future treatments for conditions currently lacking effective solutions.

Looking ahead, Science Corporation aims to expand the field of view provided by the PRIMA chip and is working on next-generation products, with human trials expected next year. Hodak's vision for brain-computer interfaces extends beyond visual restoration, indicating a future where these technologies could revolutionize various medical applications.